ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

sildenafil

Also written as “Sildenafil”, “Sildenafil citrate” and “sildenafil citrate”.

Its studies are mostly in Erectile Dysfunction · Pulmonary Arterial Hypertension · Hypertension, Pulmonary · Sexual Dysfunctions, Psychological · Persistent Fetal Circulation Syndrome, led by 10 companies.

Drug pageSildenafil: every studyMany companies study it; this page follows only the 60 they lead. All 330 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Aug 26, 200560 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Viatrisits history only470 open or runningphase 4since Aug 26, 2005Aug 26, 2005none ahead
Strategic Science & Technologiesits history only40 open or runningphase 2since Mar 9, 2015Oct 29, 2013none ahead
Hanmi Pharmaceutical20 open or runningphase 3since Jul 30, 2013Jan 18, 2012none ahead
Daré Bioscienceits history only10 open or runningphase 1since Mar 1, 2023Mar 1, 2023none ahead
Emotional Brain NYits history only10 open or runningphase 2since Aug 17, 2011Aug 17, 2011none ahead
Hamad Medicalits history only10 open or runningphase 3since Mar 11, 2012Mar 11, 2012none ahead
Hoffmann-La Rocheits history only10 open or runningphase 2since Oct 28, 2016Oct 28, 2016none ahead
Laboratório Teuto Brasileiro S/Aits history only10 open or runningphase 3since Mar 15, 2011Mar 15, 2011none ahead
N4 Pharma UKits history only10 open or runningphase 1since Apr 12, 2018Apr 12, 2018none ahead
Pharmtechnologyits history only10 open or runningphase 1since May 6, 2021May 6, 2021none ahead

Also a collaborator on its studies: Pfizer, BDD Pharma and ICOS.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Hanmi Pharmaceutical only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 18, 2012First study: phase 1 study in Erectile DysfunctionFirst studyNCT01514903 · 54 enrolled · Korea, Republic of
  2. Jul 30, 2013Phase 3 study in Hypertension, PulmonaryNCT01913847 · 144 enrolled · Korea, Republic of

TargetBeta

PDE5A →read by rule
“Phosphodiesterase 5A inhibitor”ChEMBL 37, by rule

Other programs on PDE5A

ProgramCompanyFurthest phaseStudies
TadalafilruleEli Lillyphase 473

Studies

All 2 Hanmi Pharmaceutical leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01913847Hypertension, Pulmonary · Korea, Republic of3UNKNOWNDec 2018144
NCT01514903Erectile Dysfunction · Korea, Republic of1CompletedDec 201154

How it is read

Names in the registry

  • “Sildenafil”, 27 entries
  • “sildenafil”, 18 entries
  • “Sildenafil citrate”, 14 entries
  • “sildenafil citrate”, 10 entries
  • “Sildenafil Citrate”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.